Relmada Therapeutics (RLMD) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.10, -3.13% vs the prior close of $3.20.
- Volume 1.28M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RLMD slides 3.1% to $3.10, a 6-month low, 4 down days in a row. Closed at $3.10, -3.13% vs the prior close of $3.20. Day range $3.07–$3.29, opened at $3.21.
RLMD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — RLMD slides 3.1% to $3.10, a 6-month low, 4 down days in a row
- Closed at $3.10, -3.13% vs the prior close of $3.20. Day range $3.07–$3.29, opened at $3.21.
- Volume was 1.28M shares, 1.0x its 50-day average of 1.25M.
- Price is -24.9% vs its 50-day average ($4.13) and -42.6% vs its 200-day average ($5.40).
- 52-week range $1.80–$8.00; today's close sits at 21% of that range, 61.3% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — RLMD dips 1.2% to $3.20, 3 down days in a row
- Closed at $3.20, -1.23% vs the prior close of $3.24. Day range $3.18–$3.35, opened at $3.27.
- Volume was 908.70K shares, 0.7x its 50-day average of 1.25M.
- Price is -23.3% vs its 50-day average ($4.17) and -40.9% vs its 200-day average ($5.41).
- 52-week range $1.80–$8.00; today's close sits at 23% of that range, 60.0% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — RLMD slides 3.6% to $3.24
- Closed at $3.24, -3.57% vs the prior close of $3.36. Day range $3.19–$3.37, opened at $3.31.
- Volume was 1.35M shares, 1.1x its 50-day average of 1.25M.
- Price is -23.2% vs its 50-day average ($4.22) and -40.2% vs its 200-day average ($5.42).
- 52-week range $1.80–$8.00; today's close sits at 23% of that range, 59.5% below the 52-week high.
Oct 13, 2026 — RLMD slides 4.3% to $3.36
- Closed at $3.36, -4.27% vs the prior close of $3.51. Day range $3.36–$3.55, opened at $3.50.
- Volume was 1.42M shares, 1.1x its 50-day average of 1.24M.
- Price is -21.2% vs its 50-day average ($4.26) and -38.1% vs its 200-day average ($5.42).
- 52-week range $1.80–$8.00; today's close sits at 25% of that range, 58.0% below the 52-week high.
Oct 12, 2026 — RLMD jumps 3.5% to $3.51
- Closed at $3.51, +3.54% vs the prior close of $3.39. Day range $3.32–$3.54, opened at $3.39.
- Volume was 1.42M shares, 1.1x its 50-day average of 1.25M.
- Price is -18.4% vs its 50-day average ($4.30) and -35.4% vs its 200-day average ($5.43).
- 52-week range $1.80–$8.00; today's close sits at 28% of that range, 56.1% below the 52-week high.
Oct 9, 2026 — RLMD jumps 6.9% to $3.39
- Closed at $3.39, +6.94% vs the prior close of $3.17. Day range $3.15–$3.54, opened at $3.18.
- Volume was 1.73M shares, 1.4x its 50-day average of 1.23M.
- Price is -21.8% vs its 50-day average ($4.34) and -37.6% vs its 200-day average ($5.44).
- 52-week range $1.80–$8.00; today's close sits at 26% of that range, 57.6% below the 52-week high.
Oct 8, 2026 — RLMD dips 2.5% to $3.17, a 6-month low, 6 down days in a row
- Closed at $3.17, -2.46% vs the prior close of $3.25. Day range $3.10–$3.32, opened at $3.23.
- Volume was 1.89M shares, 1.5x its 50-day average of 1.22M.
- Price is -27.6% vs its 50-day average ($4.38) and -41.7% vs its 200-day average ($5.44).
- 52-week range $1.80–$8.00; today's close sits at 22% of that range, 60.4% below the 52-week high.
- That makes 6 straight losses.
Oct 7, 2026 — RLMD dips 0.9% to $3.25, a 6-month low, 5 down days in a row
- Closed at $3.25, -0.91% vs the prior close of $3.28. Day range $3.24–$3.36, opened at $3.26.
- Volume was 1.50M shares, 1.2x its 50-day average of 1.22M.
- Price is -26.4% vs its 50-day average ($4.42) and -40.3% vs its 200-day average ($5.45).
- 52-week range $1.80–$8.00; today's close sits at 23% of that range, 59.4% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — RLMD slides 5.7% to $3.28, a 6-month low, 4 down days in a row
- Closed at $3.28, -5.75% vs the prior close of $3.48. Day range $3.27–$3.50, opened at $3.50.
- Volume was 1.74M shares, 1.4x its 50-day average of 1.20M.
- Price is -26.4% vs its 50-day average ($4.46) and -39.8% vs its 200-day average ($5.45).
- 52-week range $1.80–$8.00; today's close sits at 24% of that range, 59.0% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — RLMD slides 3.3% to $3.48, a 6-month low, 3 down days in a row
- Closed at $3.48, -3.33% vs the prior close of $3.60. Day range $3.41–$3.70, opened at $3.60.
- Volume was 1.28M shares, 1.1x its 50-day average of 1.21M.
- Price is -22.6% vs its 50-day average ($4.49) and -36.2% vs its 200-day average ($5.45).
- 52-week range $1.80–$8.00; today's close sits at 27% of that range, 56.5% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — RLMD dips 1.6% to $3.60, a 6-month low
- Closed at $3.60, -1.64% vs the prior close of $3.66. Day range $3.60–$3.73, opened at $3.72.
- Volume was 1.21M shares, 1.0x its 50-day average of 1.21M.
- Price is -20.5% vs its 50-day average ($4.53) and -34.1% vs its 200-day average ($5.46).
- 52-week range $1.80–$8.00; today's close sits at 29% of that range, 55.0% below the 52-week high.
RLMD latest news & SEC filings
Every SEC filing by or about RLMD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shenouda Maged bought 79,800 shares at $4.25 (≈$339.15K) on Sep 10, 2026
- Shenouda Maged bought 79,800 shares at $4.25 (≈$339.15K) on Sep 10, 2026
- Shenouda Maged bought 79,800 shares at $4.25 (≈$339.15K) on Sep 10, 2026
- Shenouda Maged bought 79,800 shares at $4.25 (≈$339.15K) on Sep 10, 2026
- Shenouda Maged bought 120,200 shares at $4.20 (≈$504.84K) on Sep 9, 2026
- Shenouda Maged bought 120,200 shares at $4.20 (≈$504.84K) on Sep 9, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Traversa Sergio bought 100,000 shares at $4.10 (≈$410.00K) on Sep 10, 2026
- Traversa Sergio bought 100,000 shares at $4.10 (≈$410.00K) on Sep 10, 2026
- Traversa Sergio bought 100,000 shares at $4.10 (≈$410.00K) on Sep 10, 2026
- Traversa Sergio bought 100,000 shares at $4.10 (≈$410.00K) on Sep 10, 2026
- Traversa Sergio bought 100,000 shares at $4.18 (≈$418.00K) on Sep 9, 2026
- Traversa Sergio bought 100,000 shares at $4.18 (≈$418.00K) on Sep 9, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$12.91M (prior year -$9.87M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.11 (prior year -$0.30) (loss narrowed vs Jun 30, 2025)
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 22, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RLMD
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 20, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.92% (largest 10.8%).
- Liquidity: about 1.25M shares (≈$3.86M) trade per day on average.
- 52-week position: $3.10 vs a range of $1.80–$8.00 (21% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Maged Shenouda bought 79,800 shares on Sep 10, 2026.
- Latest filings: 8-K Sep 8, 2026; 8-K Aug 6, 2026; 10-Q Aug 6, 2026.
- Share count: 106.67M shares outstanding (Aug 4, 2026), +221.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RLMD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.21 | 3.29 | 3.07 | 3.10 | 1.28M |
| Oct 15, 2026 | 3.27 | 3.35 | 3.18 | 3.20 | 908.70K |
| Oct 14, 2026 | 3.31 | 3.37 | 3.19 | 3.24 | 1.35M |
| Oct 13, 2026 | 3.50 | 3.55 | 3.36 | 3.36 | 1.42M |
| Oct 12, 2026 | 3.39 | 3.54 | 3.32 | 3.51 | 1.42M |
| Oct 9, 2026 | 3.18 | 3.54 | 3.15 | 3.39 | 1.73M |
| Oct 8, 2026 | 3.23 | 3.32 | 3.10 | 3.17 | 1.89M |
| Oct 7, 2026 | 3.26 | 3.36 | 3.24 | 3.25 | 1.50M |
| Oct 6, 2026 | 3.50 | 3.50 | 3.27 | 3.28 | 1.74M |
| Oct 5, 2026 | 3.60 | 3.70 | 3.41 | 3.48 | 1.28M |
| Oct 2, 2026 | 3.72 | 3.73 | 3.60 | 3.60 | 1.21M |
| Oct 1, 2026 | 3.73 | 3.80 | 3.65 | 3.66 | 1.36M |
| Sep 30, 2026 | 3.78 | 3.85 | 3.72 | 3.77 | 999.50K |
| Sep 29, 2026 | 3.82 | 3.89 | 3.69 | 3.73 | 863.50K |
| Sep 28, 2026 | 3.80 | 3.86 | 3.71 | 3.79 | 986.60K |
| Sep 25, 2026 | 3.81 | 3.87 | 3.73 | 3.83 | 1.31M |
| Sep 24, 2026 | 3.74 | 3.88 | 3.66 | 3.81 | 1.33M |
| Sep 23, 2026 | 4.26 | 4.26 | 3.77 | 3.78 | 1.13M |
| Sep 22, 2026 | 4.16 | 4.27 | 4.14 | 4.24 | 662.70K |
| Sep 21, 2026 | 4.13 | 4.24 | 4.07 | 4.16 | 551.60K |
About Relmada Therapeutics
Relmada Therapeutics (RLMD) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CORAL GABLES, FL. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1553643.
RLMD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Charles J Casamento | Director | Dec 16, 2025 |
| Fabiana Fedeli | Director | Dec 16, 2025 |
| John Glasspool | Director | Dec 16, 2025 |
| Paul Edward Kelly | COO | Dec 16, 2025 |
| Sergio Traversa | Chief Executive Officer | Sep 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Chuck Ence | CA and CO | Dec 16, 2025 |
| Paul Edward Kelly | COO | Dec 16, 2025 |
| Maged Shenouda | Chief Financial Officer | Sep 11, 2026 |
| Sergio Traversa | Chief Executive Officer | Sep 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 10, 2026 | Maged Shenouda | Buy | 79,800 | $4.25 |
| Sep 10, 2026 | Maged Shenouda | Buy | 79,800 | $4.25 |
| Sep 10, 2026 | Maged Shenouda | Buy | 79,800 | $4.25 |
| Sep 10, 2026 | Maged Shenouda | Buy | 79,800 | $4.25 |
| Sep 10, 2026 | Sergio Traversa | Buy | 100,000 | $4.10 |
| Sep 10, 2026 | Sergio Traversa | Buy | 100,000 | $4.10 |
| Sep 10, 2026 | Sergio Traversa | Buy | 100,000 | $4.10 |
| Sep 10, 2026 | Sergio Traversa | Buy | 100,000 | $4.10 |
| Sep 9, 2026 | Maged Shenouda | Buy | 120,200 | $4.20 |
| Sep 9, 2026 | Maged Shenouda | Buy | 120,200 | $4.20 |
| Sep 9, 2026 | Maged Shenouda | Buy | 120,200 | $4.20 |
| Sep 9, 2026 | Maged Shenouda | Buy | 120,200 | $4.20 |
| Sep 9, 2026 | Sergio Traversa | Buy | 100,000 | $4.18 |
| Sep 9, 2026 | Sergio Traversa | Buy | 100,000 | $4.18 |
| Sep 9, 2026 | Sergio Traversa | Buy | 100,000 | $4.18 |
RLMD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-57.39M | -1.45 | $-45.79M |
| Dec 31, 2024 | — | $-79.98M | -2.65 | $-51.76M |
| Dec 31, 2023 | — | $-98.79M | -3.28 | $-51.66M |
| Dec 31, 2022 | — | $-157.04M | -5.30 | $-103.80M |
| Dec 31, 2021 | — | $-125.75M | -7.16 | $-91.87M |
Latest balance sheet: total assets $219.06M, total liabilities $12.50M, cash $11.33M (as of Jun 30, 2026).
RLMD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.37 |
| May 12, 2026 | 8-K Item 2.02 (results) | $7.45 |
| Mar 20, 2026 | 8-K Item 2.02 (results) | $6.07 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $3.88 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $0.60 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $0.30 |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
| Aug 8, 2023 | 8-K Item 2.02 (results) | — |
| May 11, 2023 | 8-K Item 2.02 (results) | — |
| Mar 23, 2023 | 8-K Item 2.02 (results) | — |
| Nov 10, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on RLMD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.